Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 ...(with moderate to severe DN. -- Dow Ag...),Health

-- Dow AgroSciences has the option to exercise a commercial license for

the use of our ZFP technology in plant agriculture in the second half

of 2008.

-- The Phase 2 trial that Sangamo plans to initiate in the first quarter

of 2008 evaluating the mobilization of aldehyde bright stem cells in

subjects with diabetic neuropathy after treatment with the SB-509.

-- Plans for a Phase 2 trial of SB-509 for the treatment of ALS will also

be outlined at the briefing. Sangamo expects to initiate this trial in

the first half of 2008.

-- Plans to initiate a Phase 1 trial of a ZFP Therapeutic to treat

glioblastoma in the first half of 2008 and a Phase 1 trial for a ZFP

Therapeutic to treat HIV infection in the second half of 2008.

-- Sangamo expects to report data from the Phase 1 clinical programs in

critical limb ischemia, the severe form of peripheral artery disease in

2008.

-- Sangamo estimates that it expects to end 2008 with approximately $55M

in cash and cash equivalents, based on current expense projections and

expected progress in existing corporate relationships.

The presentation from today's Investor and Analyst Briefing will be archived on Sangamo's website until December 20, 2007 and is available at via a link on the Sangamo BioSciences website in the Investor section http://investor.sangamo.com/index.cfm under "Events and Presentations."

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing
'/>"/>